At a glance
- Cortagen is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 15 publications mentioning it, including 0 randomized controlled trials and 12 animal-only studies.
- No study registered on ClinicalTrials.gov tests it as an intervention.
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN.
- EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON "AGED" HETEROCHROMATIN.
- [Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia].
- [Effects of epithalon and cortagene on immunity and hemostasis in neonatally hypophysectomized chicken and old birds].
- Effects of bioactive tetrapeptides on free-radical processes.
- Production of lymphocyte-activating factors by mouse macrophages during aging and under the effect of short peptides.
- Synthesis of IL-2 mRNA in cells of rat hypothalamic structures after injection of short peptides.
- Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray.
- Effects of short peptides on lymphocyte chromatin in senile subjects.
- In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
No registered study on ClinicalTrials.gov lists this peptide as an intervention.
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.